This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Trials in Progress
    • Trials in Progress
      • Bladder Cancer
        • IMMORTAL
      • Kidney Cancer
        • RadiCal
    • Middle Side
      • Prostate Cancer
        • ARAMON
        • ARASEC
        • ARASTEP
        • ECLIPSE
        • FORT
        • NRG-GU 0101
        • Masofaniten (Oral EPI-7386)
        • RTIRE
        • SHORTER
        • SPLASH
    • Right Side
      • PCCTC
        • DORA
        • IRONMAN
        • PROMISE
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
          • Trimodality Therapy
            Leslie Ballas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Endourology
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Pelvic Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Suprapubic Catheter
        Diane K. Newman, DNP FAAN BCB-PMD
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Medical Education
      • Covid-19
      • The Prostate Cancer Foundation
      • Health Policy in Urological Diseases
      • Disparities: Social Determinants of Health
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Testicular Cancer
      • Endourology
    • Pelvic Health & Reconstruction
      • Pelvic Health & Reconstruction
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • AMA Interim 2023
      • SUO 2023
      • ESMO 2023
      • IBCN 2023
      • ASTRO 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology

Prostate Cancer

Recent Abstracts
Digoxin may be a possible treatment for prostate cancer April 4, 2011
BJUI Mini Reviews - The influence of family history on prostate cancer risk: Implications for clinical management April 4, 2011
Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography - Abstract April 1, 2011
Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer - Abstract April 1, 2011
High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: Analysis of short- and medium-term urinary toxicity and biochemical control - Abstract April 1, 2011
A single center prospective study: Prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy - Abstract April 1, 2011
Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study - Abstract April 1, 2011
A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy - Abstract April 1, 2011
Overuse of imaging for staging low risk prostate cancer - Abstract April 1, 2011
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range - Abstract April 1, 2011
The relationship between prostate specific antigen change and biopsy progression in patients with prostate cancer on active surveillance - Abstract April 1, 2011
Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy - Abstract April 1, 2011
A biopsychosocial approach to sexual recovery after prostate cancer surgery: The role of grief and mourning - Abstract April 1, 2011
Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: Effect of percentage of the ductal component and associated grade of acinar adenocarcinoma - Abstract March 31, 2011
The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer" - Abstract March 31, 2011
The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score - Abstract March 31, 2011
Androgen suppression strategies for prostate cancer: Is there an ideal approach? - Abstract March 31, 2011
The implication of initial 24-core transrectal prostate biopsy protocol on the detection of significant prostate cancer and high grade prostatic intraepithelial neoplasia - Abstract March 31, 2011
3D-conformal hypofractionated radiotherapy for prostate cancer with daily transabdominal ultrasonography prostate localization: Toxicity and outcome of a pilot study - Abstract March 31, 2011
Radical prostatectomy for high-risk clinically localized prostate cancer: A prospective single institution series - Abstract March 31, 2011
Page 1332 of 1351
  • Start
  • Prev
  • 1327
  • 1328
  • 1329
  • 1330
  • 1331
  • 1332
  • 1333
  • 1334
  • 1335
  • 1336
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free